Choosing a Multiplexed Imaging Method: Plex, Resolution, and Tissue Compatibility

Multiplex imaging has become central to spatial proteomics, but the expanding platform landscape makes method selection difficult. Cyclic fluorescence approaches, laser-ablation mass spectrometry, and ion-beam imaging each impose different constraints on plex, resolution, tissue handling, and throughput, as outlined in the spatial proteomics methods guide. Choosing among them demands a structured approach: the platform that maximizes protein targets may be incompatible with archival specimens, while the highest-resolution option may be too slow for cohort-scale studies.

Multiplexed imaging method families at a glance

At the level of detection physics, multiplexed tissue imaging methods divide into two classes: those that use optical fluorescence readouts and those that use mass spectrometry to quantify metal-tagged antibodies.

Cyclic fluorescence methods, including tissue-based CyCIF (t-CyCIF) and the PhenoCycler system (formerly COdetection by inDEXing, or CODEX), repeatedly stain, image, and strip reporter signal from the same tissue section across multiple rounds. In t-CyCIF, conventional fluorophore-conjugated antibodies are applied and imaged before fluorophores are chemically bleached. In PhenoCycler, a full antibody panel conjugated to unique DNA barcodes is applied in a single staining step, and fluorescently labeled complementary oligonucleotide probes are hybridized, imaged, and stripped in sequential reveal cycles. Both approaches use conventional fluorescence microscopy hardware, which is a meaningful practical advantage for labs with existing infrastructure.

Mass spectrometry-based methods replace fluorophores with metal isotopes, which carry no endogenous background in tissue and do not suffer from spectral overlap. IMC uses a pulsed ultraviolet laser to ablate metal-tagged tissue in a raster pattern, with the released ions quantified by time-of-flight (TOF) mass spectrometry in a single acquisition pass. MIBI instead uses a focused primary ion beam to sputter reporter ions from tissue, detecting all targets simultaneously by TOF mass spectrometry. The core distinction between IMC and MIBI is the excitation source (laser ablation versus ion-beam bombardment), with significant consequences for spatial resolution and throughput. A 2022 overview in Nature Methods noted that all these approaches share antibody-based target specificity and the capacity to resolve cell types and tissue architecture at single-cell resolution, regardless of detection modality.

Figure 1: A two-panel schematic contrasting cyclic fluorescence imaging (stain, image, strip, repeat) with single-pass mass spectrometry imaging (stain once, ablate, detect simultaneously) as the two principal workflows in multiplexed tissue proteomics. Credit: AI-generated image created using Google Gemini (2026).

Plex vs resolution trade-offs in high-plex imaging

Plex capacity and spatial resolution do not improve in tandem across platforms, and understanding this relationship is fundamental to platform selection.

Cyclic fluorescence methods achieve the highest practical plex through iteration: each round images three to five markers, and the panel grows with additional cycles. PhenoCycler's DNA-barcode architecture has demonstrated 50 or more cellular markers in published studies, while t-CyCIF has been applied to panels of more than 60 protein targets in human tumor tissue. Each cycle adds hours of run time, so large panels can require multiple days of acquisition per slide. Spatial resolution for optical platforms using a 20× objective is approximately 350–400 nanometers (nm) per pixel, sufficient to distinguish cell membranes and nuclei but well short of subcellular compartment resolution.

Mass spectrometry-based platforms are single-pass: all markers are simultaneously detected after a single staining step, which simplifies the workflow and eliminates the registration artifacts that can accumulate across cyclic rounds. IMC achieves a standard spatial resolution of 1 micrometer (µm) and has been applied to image up to 40 protein targets in a single tissue section. MIBI takes the resolution advantage further through ion-beam physics: the foundational MIBI-TOF instrument demonstrated pixel resolution of 260 nm, fields of view up to 800 µm × 800 µm, a five-log dynamic range, and simultaneous imaging of 36 labeled antibodies in a single acquisition.

The practical consequence is that plex ceilings for IMC and MIBI are set less by the detection method than by reagent availability: the catalog of antibodies validated for metal-isotope conjugation is smaller than that validated for fluorescence. Cyclic fluorescence methods can access a far broader antibody ecosystem, which is a decisive factor for any experiment targeting less-characterized antigens.

Table 1: Comparison of published performance parameters for the four major multiplexed tissue imaging platforms. Plex values reflect reported published studies rather than vendor specifications and should be verified against current reagent availability before panel design. Sources for all numerical values are cited in the surrounding text.

Tissue and antibody constraints for multiplexed imaging

All four platforms support FFPE tissue, which is the format of most clinical archives and retrospective cohort material. However, compatibility is not uniform across sample types, and specific tissue constraints can eliminate candidate platforms before plex or resolution considerations even arise.

PhenoCycler panels are primarily designed and commercially validated for fresh frozen tissue, where antigen preservation is more predictable. Published protocols for FFPE material exist and continue to expand, but panel antibodies require individual validation on each fixation batch, and antigen retrieval conditions optimized for one target can compromise others. IMC and MIBI require no cyclic processing, which subjects the tissue to fewer handling steps during acquisition and can preserve fragile archival specimens better than iterative staining methods. IMC supports both FFPE and fresh frozen tissue and has a well-developed published literature in tumor microenvironment research using archival FFPE material. MIBI is most commonly applied to FFPE in published studies.

CyCIF supports both FFPE and fresh frozen tissue formats, and its use of standard fluorophore-conjugated antibodies means panel validation can draw on existing immunohistochemistry and immunofluorescence antibody databases. This is the practical distinction between multiplexed immunofluorescence approaches such as CyCIF and metal-tag platforms such as IMC and MIBI: fluorescence methods draw on a far broader validated antibody ecosystem, while metal-tag platforms require antibodies conjugated to stable metal isotopes through vendor-supplied or custom conjugation pipelines. Researchers targeting emerging or niche antigens may find the pre-conjugated reagent catalog for IMC and MIBI significantly smaller than for fluorescence-based approaches.

Practical considerations before platform selection:

• Tissue format. FFPE archives favor IMC or MIBI, while fresh frozen material opens all four options.
• Panel specificity. Broad immune-phenotyping panels are well served by all platforms. Novel or niche targets require checking conjugated reagent availability against each platform's catalog.
• Antigen retrieval. FFPE panels require retrieval optimization for each target. Incompatible retrieval conditions within a panel are a common failure mode for high-plex FFPE workflows.
• Sample area. IMC fields of view are typically smaller per acquisition than PhenoCycler or CyCIF whole-slide imaging sessions, so large tissue areas require tiled acquisitions.
• Archival study design. Retrospective FFPE cohort studies favor single-pass mass spectrometry platforms for reasons of sample integrity and acquisition reproducibility across batches.

Throughput, cost, and access in multiplexed imaging

Throughput varies by more than an order of magnitude across platforms, and cost implications depend heavily on whether access is through a core facility or individual instrument ownership.

Circulating Immune Proteins in Liver Cancer Research

This webinar explores how circulating immune-related proteins can improve our understanding of hepatocellular and gallbladder cancer risk across diverse populations with viral hepatitis.
View Webinar

Advertisement

Among cyclic fluorescence methods, PhenoCycler's automated fluidics and integrated imaging pipeline deliver the highest throughput, processing multiple slides through reveal cycles without manual intervention. CyCIF is powerful but requires more manual coordination between staining, bleaching, and imaging steps. A 60-marker panel may take several days of continuous acquisition on a single slide. For cohort-scale studies, the cumulative time cost of the bleach-and-repeat protocol is a genuine operational constraint.

Among mass spectrometry platforms, IMC generally offers faster per-area acquisition than MIBI, as the two methods use different excitation physics with different scan-rate ceilings. MIBI's resolution advantage comes at a direct throughput cost: imaging at 260 nm pixel resolution across a large tissue area requires considerably more time than imaging at 1 µm. For studies focused on cell-type mapping and neighborhood analysis, the throughput penalty may outweigh the resolution gain. For questions requiring submicron spatial precision and subcellular protein localization, MIBI's performance is not matched by any other platform.

On cost, CyCIF has the most accessible entry point: labs with existing widefield fluorescence microscopes can implement it using commercial antibody conjugation kits without a capital instrument purchase. PhenoCycler requires the dedicated PhenoCycler fluidics unit paired with a compatible imaging system. IMC and MIBI are typically accessed through core facilities given instrument costs, though per-sample costs at a shared facility scale more predictably with run time and panel size. A multiplex imaging optimization framework published in Communications Biology in 2022 identified pipeline selection as inseparable from infrastructure and cost constraints, a conclusion that holds across all four platforms.

A multiplex imaging method-selection framework

The following framework organizes method selection around the constraint most likely to be binding for a given experimental context. Selection proceeds by identifying that constraint and tracing it to the platform it most directly favors.

1. Spatial resolution is the primary requirement. Scientific questions requiring subcellular protein localization, plasma membrane boundary resolution, or imaging below 500 nm call for MIBI. The throughput and cost implications must be factored into experimental design from the outset.
2. Maximum plex with broad antibody access is the primary requirement. Panels targeting more than 40 proteins, particularly those where many antigens lack validated metal-conjugation reagents, are best served by PhenoCycler or CyCIF. PhenoCycler offers higher throughput and greater automation, while CyCIF offers lower instrument cost and compatibility with existing microscopes. CyCIF-based methods are described in depth in the cyclic immunofluorescence methods article.
3. Single-pass acquisition and freedom from autofluorescence are priorities. Highly pigmented tissues, aged FFPE material with elevated background, or samples too precious or fragile for cyclic processing are well suited to IMC. Single-pass acquisition, 40-marker capacity, and an established FFPE workflow make IMC the most practical path for this context. A 2024 review in Cancer Discovery outlined IMC and MIBI workflows for clinical and translational applications, noting the advantages of metal-tag detection in archival pathology material.
4. Infrastructure access and cost are the binding constraint. Labs without dedicated instrument budgets and without core facility access to mass-spectrometry-based platforms should prioritize CyCIF. Open-source protocols, broad antibody compatibility, and existing-microscope compatibility make it the lowest-barrier entry into high-plex imaging without capital expenditure.
5. Retrospective FFPE cohort studies require high sample throughput. IMC represents the best practical balance for this context: established FFPE compatibility, no cyclic tissue stress, moderate per-sample acquisition time, and a well-validated reagent ecosystem for commonly studied immune and stromal markers.

Making the multiplex imaging decision

No platform occupies all quadrants of the plex-resolution-throughput space, and the practical constraints of tissue type and antibody availability frequently resolve the choice before instrument specifications become the determining factor. For researchers approaching this decision for the first time, the spatial biology methods landscape situates these platforms within the broader context of spatial omics approaches, and the framework above is most useful when applied alongside a realistic audit of which target antigens have validated conjugated reagents available.

As the field matures, comparative analyses of platforms applied to the same tissue type and target panel will become more common. A 2024 analysis in the British Journal of Cancer noted that three-dimensional multiplex imaging of serial sections using both IMC and CyCIF is an emerging approach that exploits the orthogonal strengths of each method. In the near term, the choice between cyclic fluorescence and single-pass mass spectrometry imaging is less likely to be resolved by a single benchmark paper than by the combination of markers targeted, tissue available, and throughput required for each specific research program.

This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.